CA2103040A1 - Utilisation d'une composition pharmaceutique contenant de la purpurogalline comme agent antioxydant et cytoprotecteur - Google Patents

Utilisation d'une composition pharmaceutique contenant de la purpurogalline comme agent antioxydant et cytoprotecteur

Info

Publication number: CA2103040A1
Authority: CA; Canada
Prior art keywords: purpurogallin; blood; composition; vivo; effective amount
Prior art date: 1991-05-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002103040A

Other languages

English (en)

Inventor

Tai-Wing Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-16

Filing date

1992-05-15

Publication date

1992-11-17

1992-05-15 Application filed by Individual filed Critical Individual

1992-11-17 Publication of CA2103040A1 publication Critical patent/CA2103040A1/fr

Status Abandoned legal-status Critical Current

Links

WDGFFVCWBZVLCE-UHFFFAOYSA-N purpurogallin Chemical compound C1=CC=C(O)C(=O)C2=C1C=C(O)C(O)=C2O WDGFFVCWBZVLCE-UHFFFAOYSA-N 0.000 title claims abstract description 136
230000001120 cytoprotective effect Effects 0.000 title claims abstract description 10
239000003963 antioxidant agent Substances 0.000 title claims description 18
230000003078 antioxidant effect Effects 0.000 title claims description 13
239000003795 chemical substances by application Substances 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 title description 2
210000004369 blood Anatomy 0.000 claims abstract description 24
239000008280 blood Substances 0.000 claims abstract description 24
239000000203 mixture Substances 0.000 claims abstract description 17
229930182478 glucoside Natural products 0.000 claims abstract description 7
150000008131 glucosides Chemical class 0.000 claims abstract description 6
238000000034 method Methods 0.000 claims description 18
210000000056 organ Anatomy 0.000 claims description 17
150000003254 radicals Chemical class 0.000 claims description 16
208000028867 ischemia Diseases 0.000 claims description 13
230000037396 body weight Effects 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 8
230000010410 reperfusion Effects 0.000 claims description 7
230000003247 decreasing effect Effects 0.000 claims description 6
230000001590 oxidative effect Effects 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
229930182470 glycoside Natural products 0.000 claims 2
150000002338 glycosides Chemical class 0.000 claims 2
230000000451 tissue damage Effects 0.000 claims 2
231100000827 tissue damage Toxicity 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 1
239000012530 fluid Substances 0.000 claims 1
239000002504 physiological saline solution Substances 0.000 claims 1
230000006378 damage Effects 0.000 abstract description 7
238000001356 surgical procedure Methods 0.000 abstract description 4
206010063837 Reperfusion injury Diseases 0.000 abstract description 3
208000012947 ischemia reperfusion injury Diseases 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 19
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 18
235000006708 antioxidants Nutrition 0.000 description 13
239000000243 solution Substances 0.000 description 12
210000003494 hepatocyte Anatomy 0.000 description 11
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
108010093894 Xanthine oxidase Proteins 0.000 description 9
239000001301 oxygen Substances 0.000 description 9
229910052760 oxygen Inorganic materials 0.000 description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 7
102100033220 Xanthine oxidase Human genes 0.000 description 7
239000000654 additive Substances 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
230000000996 additive effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000017074 necrotic cell death Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
229930003427 Vitamin E Natural products 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
235000019165 vitamin E Nutrition 0.000 description 4
239000011709 vitamin E Substances 0.000 description 4
229940046009 vitamin E Drugs 0.000 description 4
LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000000107 myocyte Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
210000000013 bile duct Anatomy 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
229940124569 cytoprotecting agent Drugs 0.000 description 2
XCFVSYWEMCQEOH-UHFFFAOYSA-L disodium 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].NC1=C(C(=CC2=CC(=CC(=C12)O)S(=O)(=O)[O-])S(=O)(=O)[O-])N=NC1=CC=C(C=C1)[N+](=O)[O-] XCFVSYWEMCQEOH-UHFFFAOYSA-L 0.000 description 2
230000000694 effects Effects 0.000 description 2
JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 2
229960000305 enflurane Drugs 0.000 description 2
239000003925 fat Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
210000002767 hepatic artery Anatomy 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000004792 oxidative damage Effects 0.000 description 2
210000003240 portal vein Anatomy 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
-1 purpuro-gallin glucosides Chemical class 0.000 description 2
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
238000000527 sonication Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
238000007725 thermal activation Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
239000011627 DL-alpha-tocopherol Substances 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010056328 Hepatic ischaemia Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
230000032683 aging Effects 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical class 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000008148 cardioplegic solution Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000446 fuel Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000007866 hepatic necrosis Effects 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000002156 mixing Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010525 oxidative degradation reaction Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
210000005164 penile vein Anatomy 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
229940079877 pyrogallol Drugs 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
230000003578 releasing effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
WZODLFCLKIXWGA-UHFFFAOYSA-N sodium 4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonic acid Chemical compound CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O.[Na+] WZODLFCLKIXWGA-UHFFFAOYSA-N 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000004449 solid propellant Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002103040A 1991-05-16 1992-05-15 Utilisation d'une composition pharmaceutique contenant de la purpurogalline comme agent antioxydant et cytoprotecteur Abandoned CA2103040A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US70104791A	1991-05-16	1991-05-16
US701,047		1991-05-16

Publications (1)

Publication Number	Publication Date
CA2103040A1 true CA2103040A1 (fr)	1992-11-17

Family

ID=24815854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002103040A Abandoned CA2103040A1 (fr)	1991-05-16	1992-05-15	Utilisation d'une composition pharmaceutique contenant de la purpurogalline comme agent antioxydant et cytoprotecteur

Country Status (6)

Country	Link
EP (1)	EP0584148A1 (fr)
JP (1)	JPH06507610A (fr)
AU (1)	AU1745592A (fr)
CA (1)	CA2103040A1 (fr)
HU (1)	HUT66375A (fr)
WO (1)	WO1992020332A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0892157A (ja) *	1994-05-02	1996-04-09	F Hoffmann La Roche Ag	プルプロガリン誘導体
EP2296760B1 (fr) *	2008-06-25	2016-03-16	Basf Se	Utilisation de dérivés de benzotropolone en tant qu'absorbeurs uv et antioxydants, et leur utilisation dans des écrans solaires et/ou des compositions cosmétiques
KR101748806B1 (ko)	2016-02-29	2017-06-19	대구대학교 산학협력단	Purpurogallin을 유효성분으로 함유하는 멜라닌 생성 억제 화장료 조성물 및 그 제조방법
KR102040230B1 (ko) *	2017-09-25	2019-11-04	제주대학교 산학협력단	푸르푸로갈린을 포함하는, 활성산소종, 자외선 또는 미세먼지에 대한 피부 보호용 화장료 조성물
CN110128290B (zh) *	2019-05-10	2022-04-29	江苏耐雀生物工程技术有限公司	红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4181545A (en) *	1977-04-28	1980-01-01	United Technologies Corporation	Hydroxylic aromatic compounds as additives for rubber-based, composite solid propellants
US4919915A (en) *	1987-03-03	1990-04-24	Paul Averback	Method for detecting the ability to prevent red-to-green congophilic birefringence
EP0290442A4 (fr) *	1986-11-19	1990-07-03	Chemex Pharmaceuticals Inc	Composes pharmacologiquement actifs et leurs melanges, compositions organiques et sels metalliques.
DK36389A (da) *	1988-02-05	1989-08-06	Eastman Kodak Co	Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion

1992
- 1992-05-15 WO PCT/CA1992/000204 patent/WO1992020332A1/fr not_active Ceased
- 1992-05-15 EP EP92909999A patent/EP0584148A1/fr not_active Withdrawn
- 1992-05-15 HU HU9303246A patent/HUT66375A/hu unknown
- 1992-05-15 JP JP4509614A patent/JPH06507610A/ja active Pending
- 1992-05-15 CA CA002103040A patent/CA2103040A1/fr not_active Abandoned
- 1992-05-15 AU AU17455/92A patent/AU1745592A/en not_active Abandoned

Also Published As

Publication number	Publication date
HUT66375A (en)	1994-11-28
WO1992020332A1 (fr)	1992-11-26
AU1745592A (en)	1992-12-30
EP0584148A1 (fr)	1994-03-02
JPH06507610A (ja)	1994-09-01
HU9303246D0 (en)	1994-03-28

Publication	Publication Date	Title
Meerson et al.	1982	The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart
Cavarocchi et al.	1986	Superoxide generation during cardiopulmonary bypass: is there a role for vitamin E?
Schoenberg et al.	1985	Studies on the oxygen radical mechanism involved in the small intestinal reperfusion damage
Babizhayev et al.	1994	Lipid peroxide and reactive oxygen species generating systems of the crystalline lens
Mickle et al.	1989	Myocardial salvage with trolox and ascorbic acid for an acute evolving infarction
Drossos et al.	1995	Deferoxamine cardioplegia reduces superoxide radical production in human myocardium
Bautista et al.	1990	Superoxide anion generation by in situ perfused rat liver: effect of in vivo endotoxin
MANABE et al.	1987	Effects of essential oils on erythrocytes and hepatocytes from rats and dipalmitoyl phosphatidylcholine-liposomes
Sasaki et al.	1995	A protective role for glutathione-dependent reduction of dehydroascorbic acid in lens epithelium.
Ouriel et al.	1985	Protection of the kidney after temporary ischemia: free radical scavengers
Jiménez et al.	2000	Protective effects of boldine against free radical‐induced erythrocyte lysis
Lawlor et al.	1995	Astaxanthin: antioxidant effects in chicken embryo fibroblasts
AU5282493A (en)	1994-05-09	Use of a cell membrane permeant calcium buffer for reducing injury of mammalian cells in vivo
US4039682A (en)	1977-08-02	Method and composition for relief of back pain
US5047395A (en)	1991-09-10	Reduction of oxyradical damage in biomedical applications
Gehring et al.	1971	The cataractogenic activity of chemical agents
WO1999008514A1 (fr)	1999-02-25	Compositions contenant du polyethylene glycol et leurs utilisations
Shivaram et al.	1998	The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria
CA2103040A1 (fr)	1992-11-17	Utilisation d'une composition pharmaceutique contenant de la purpurogalline comme agent antioxydant et cytoprotecteur
JPH01265022A (ja)	1989-10-23	哺乳動物の組織を再潅流損傷から守る組成物及び方法
US5248668A (en)	1993-09-28	Use of purpurogallin and glycosides thereof in treating ischemia in mammals
US5099012A (en)	1992-03-24	Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
Chakraborty et al.	1988	Effect of erythropoietin on membrane lipid peroxidation, superoxide dismutase, catalase, and glutathione peroxidase of rat RBC
Stone et al.	1989	The role of antioxidant nutrients in preventing hyperbaric oxygen damage to the retina
WO1993010784A1 (fr)	1993-06-10	Composition et procede therapeutiques de prevention de lesions occasionnees par perfusion

Legal Events

Date	Code	Title	Description
1997-05-15	FZDE	Dead